Bioelectronics Corp Stock Performance
| BIEL Stock | USD 0.0003 0.0001 25.00% |
Bioelectronics Corp holds a performance score of 5 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 8.97, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bioelectronics Corp will likely underperform. Use Bioelectronics Corp sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to analyze future returns on Bioelectronics Corp.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bioelectronics Corp are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite quite fragile technical and fundamental indicators, Bioelectronics Corp disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Bioelectronics |
Bioelectronics Corp Relative Risk vs. Return Landscape
If you would invest 0.05 in Bioelectronics Corp on October 31, 2025 and sell it today you would lose (0.01) from holding Bioelectronics Corp or give up 20.0% of portfolio value over 90 days. Bioelectronics Corp is currently generating 1.3333% in daily expected returns and assumes 18.9851% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Bioelectronics, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bioelectronics Corp Target Price Odds to finish over Current Price
The tendency of Bioelectronics Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.0003 | 90 days | 0.0003 | about 75.41 |
Based on a normal probability distribution, the odds of Bioelectronics Corp to move above the current price in 90 days from now is about 75.41 (This Bioelectronics Corp probability density function shows the probability of Bioelectronics Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 8.97 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Bioelectronics Corp will likely underperform. In addition to that Bioelectronics Corp has an alpha of 2.034, implying that it can generate a 2.03 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bioelectronics Corp Price Density |
| Price |
Predictive Modules for Bioelectronics Corp
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bioelectronics Corp. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Bioelectronics Corp's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Bioelectronics Corp Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bioelectronics Corp is not an exception. The market had few large corrections towards the Bioelectronics Corp's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bioelectronics Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bioelectronics Corp within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.03 | |
β | Beta against Dow Jones | 8.97 | |
σ | Overall volatility | 0.000064 | |
Ir | Information ratio | 0.12 |
Bioelectronics Corp Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bioelectronics Corp for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bioelectronics Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bioelectronics Corp is way too risky over 90 days horizon | |
| Bioelectronics Corp has some characteristics of a very speculative penny stock | |
| Bioelectronics Corp appears to be risky and price may revert if volatility continues | |
| Bioelectronics Corp has a very high chance of going through financial distress in the upcoming years | |
| Bioelectronics Corp currently holds 13.34 M in liabilities. Bioelectronics Corp has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bioelectronics Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Bioelectronics Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bioelectronics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bioelectronics to invest in growth at high rates of return. When we think about Bioelectronics Corp's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.61 M. Net Loss for the year was (289.82 K) with profit before overhead, payroll, taxes, and interest of 795.53 K. | |
| Bioelectronics Corp currently holds about 925 in cash with (320.3 K) of positive cash flow from operations. |
Bioelectronics Corp Fundamentals Growth
Bioelectronics Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bioelectronics Corp, and Bioelectronics Corp fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bioelectronics Pink Sheet performance.
| Return On Asset | -0.34 | |||
| Profit Margin | (0.18) % | |||
| Operating Margin | (0.09) % | |||
| Current Valuation | 52.16 M | |||
| Shares Outstanding | 24.71 B | |||
| Price To Sales | 30.73 X | |||
| Revenue | 1.61 M | |||
| EBITDA | (1.36 M) | |||
| Cash And Equivalents | 925 | |||
| Total Debt | 13.34 M | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (320.3 K) | |||
| Total Asset | 1.11 M | |||
| Retained Earnings | (28.41 M) | |||
| Current Asset | 1.11 M | |||
| Current Liabilities | 6.86 M | |||
About Bioelectronics Corp Performance
By examining Bioelectronics Corp's fundamental ratios, stakeholders can obtain critical insights into Bioelectronics Corp's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Bioelectronics Corp is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. The company was incorporated in 2000 and is headquartered in Frederick, Maryland. BIOELECTRONICS CORP operates under Medical Devices classification in the United States and is traded on OTC Exchange.Things to note about Bioelectronics Corp performance evaluation
Checking the ongoing alerts about Bioelectronics Corp for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bioelectronics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bioelectronics Corp is way too risky over 90 days horizon | |
| Bioelectronics Corp has some characteristics of a very speculative penny stock | |
| Bioelectronics Corp appears to be risky and price may revert if volatility continues | |
| Bioelectronics Corp has a very high chance of going through financial distress in the upcoming years | |
| Bioelectronics Corp currently holds 13.34 M in liabilities. Bioelectronics Corp has a current ratio of 0.01, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Bioelectronics Corp until it has trouble settling it off, either with new capital or with free cash flow. So, Bioelectronics Corp's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bioelectronics Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bioelectronics to invest in growth at high rates of return. When we think about Bioelectronics Corp's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.61 M. Net Loss for the year was (289.82 K) with profit before overhead, payroll, taxes, and interest of 795.53 K. | |
| Bioelectronics Corp currently holds about 925 in cash with (320.3 K) of positive cash flow from operations. |
- Analyzing Bioelectronics Corp's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bioelectronics Corp's stock is overvalued or undervalued compared to its peers.
- Examining Bioelectronics Corp's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bioelectronics Corp's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bioelectronics Corp's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bioelectronics Corp's pink sheet. These opinions can provide insight into Bioelectronics Corp's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Bioelectronics Pink Sheet
Bioelectronics Corp financial ratios help investors to determine whether Bioelectronics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bioelectronics with respect to the benefits of owning Bioelectronics Corp security.